Ads
related to: contraindications of ezetimibe 10
Search results
Results From The WOW.Com Content Network
The two contraindications to taking ezetimibe are a previous allergic reaction to it, including symptoms of rash, angioedema, anaphylaxis, and severe liver disease, especially when taken with a statin. [24] Ezetimibe may have significant medication interactions with ciclosporin and with fibrates other than fenofibrate. [3]
With median follow-up of 6 years, simvastatin+ezetimibe was found to reduce the primary outcome of CV mortality, major CV event, or nonfatal stroke (34.7% vs. 32.7%; P=0.016; NNT 50 per 7 years or NNT 350 per 1 year ). There was no reduction in all-cause or CV mortality with simvastatin+ezetimibe, though there was a reduction in MI and stroke. [6]
Ezetimibe/rosuvastatin, sold under the brand name Ridutrin among others, is a combination medication used to treat high cholesterol. [6] [7] In some countries it is sold as a kit or a pack containing two distinct pills. [8] [9] The combination was approved for medical use in the United States in March 2021. [4]
Bempedoic acid/ezetimibe, sold under the brand name Nexlizet among others, is a fixed-dose combination medication used for the treatment of high cholesterol. [ 1 ] [ 3 ] It is a combination of bempedoic acid and ezetimibe .
Antihypertensive agents comprise multiple classes of compounds that are intended to manage hypertension (high blood pressure). Antihypertensive therapy aims to maintain a blood pressure goal of <140/90 mmHg in all patients, as well as to prevent the progression or recurrence of cardiovascular diseases (CVD) in hypertensive patients with established CVD. [2]
Ezetimibe/atorvastatin (trade names Liptruzet, Atozet) is a cholesterol lowering combination drug. In the United States, it was approved in May 2013, by the Food and Drug Administration for the treatment of elevated low-density lipoprotein (LDL) in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet. [ 1 ]
In a randomized study it showed a LDL-C reduction of 63.6 percent, significantly more than bempedoic acid/ezetimibe, and it may also be more effective than bempedoic acid / statin combination therapy.
Colestilan (INN, trade name BindRen) is a medication that acts as a phosphate binder [1] and bile acid sequestrant. [2] It is an ion-exchange resin, is an orally administered bile acid sequestrant that is being developed by Mitsubishi Tanabe Pharma Corporation for the treatment of hypercholesterolaemia and hyperphosphataemia.